Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | Director · Chief Executive Officer | April 01, 2024 | April 03, 2024 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Director · Chief Executive Officer | October 12, 2026 | October 15, 2026 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, Head of R&D and CSO | January 21, 2020 | January 23, 2020 |
| Surrozen, Inc./DESRZN · Entity 6092 | Director | May 14, 2025 | May 15, 2025 |
| Third Harmonic Bio, Inc.THRD · Entity 76517 | Director | October 26, 2022 | October 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date April 01, 2024 · Filed April 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,577,374 |
Reported balance
After 2024-04-01 transaction · row 1
1 source rowRow 1 · 2024-04-01 · Sale · Disposed 9,961 · Balance 1,577,374 F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 487,205 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 487,205 F3: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 677,813 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 677,813 F4: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 354,969 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 354,969 F5: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 349,898 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 349,898 F6: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,070 |
Reported balance
Holding disclosure · report date 2024-04-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,070 F7: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee.
F4: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee.
F5: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power.
F6: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee.
F7: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee.
Cue Biopharma, Inc.
Report date October 12, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 694,908 |
Ending reported balance
After 2026-10-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-12 · Sale · Disposed 10,000 · Balance 695,995 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Row 2 · 2026-10-12 · Sale · Disposed 1,087 · Balance 694,908 F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold.
Horizon Therapeutics Public Ltd Co
Report date January 21, 2020 · Filed January 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 109,668 |
Ending reported balance
After 2020-01-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-21 · Grant · Acquired 6,129 · Balance 112,384 F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Row 2 · 2020-01-21 · Tax withholding · Disposed 2,716 · Balance 109,668 |
| Performance Restricted Stock Units (PSUs)SEC Table II · derivative / convertible security | Direct | 12,262 |
Reported balance
After 2020-01-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-21 · Grant · Acquired 12,262 · Balance 12,262 F2: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 21, 2020, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022.
F2: Each PSU represents a contingent right to receive one ordinary share of the Issuer.
Surrozen, Inc./DE
Report date May 14, 2025 · Filed May 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2035-05-14 | Direct | 1,333 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 1,333 · Balance 1,333 F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.
Third Harmonic Bio, Inc.
Report date October 26, 2022 · Filed October 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.83 · Expires 2032-10-25 | Direct | 13,667 |
Reported balance
After 2022-10-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-26 · Grant · Acquired 13,667 · Balance 13,667 F1: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Principia Biopharma Inc.
Report date September 28, 2020 · Filed September 28, 2020
Section 16 reporting ended · disclosed 2020-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.81 · Expires 2029-04-15 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-09-28 · Disposition to issuer · Disposed 20,475 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.77 · Expires 2029-06-10 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.66 · Expires 2030-06-03 | Direct | 0 |
Reported balance
After 2020-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-09-28 · Disposition to issuer · Disposed 10,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 15, 2026 01:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 1,087 | $28.05 | $30,490.35 |
DisclosureSEC source: 0001725092-26-000019 · form4-10152026_011031.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 694,908 F1 · kind: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Read SEC document |
| October 12, 2026 Filed Oct 15, 2026 01:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 10,000 | $27.50 | $275,000.00 |
DisclosureSEC source: 0001725092-26-000019 · form4-10152026_011031.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,995 F1 · kind: The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person. These sales were made automatically to satisfy mandatory tax withholding obligations through a "sell-to-cover" transaction in connection with the vesting and settlement of restricted stock units, and the Reporting Person did not exercise any control over the timing, price or number of shares sold. Read SEC document |
| August 13, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 10,460 | $29.48 | $308,360.80 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 6 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705,995 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F6 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $28.90 to $29.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 2,375 | $28.11 | $66,761.25 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 5 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 716,455 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F5 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.78 to $28.505, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 13, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 5,423 | $27.19 | $147,451.37 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 4 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,830 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F4 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.70 to $27.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 12, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock · Derivative | 109,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · derivative · entry 7 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,358 Underlying: Common Stock · 109,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F7 · derivative.exercise_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. F7 · derivative.expiration_date: The performance stock units ("PSU") were awarded subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. The award settled with respect to 1/3 of the PSUs underlying the award on August 12, 2026. The remaining 2/3 of the PSUs underlying the award are expected to settle on the achievement of a closing price per share of $38.50 and $44.00, in each case for a period of five consecutive trading days. Read SEC document |
| August 12, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 5,775 | $27.75 | $160,256.25 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 3 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 724,253 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F3 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $27.50 to $28.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 12, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 34,225 | $26.99 | $923,732.75 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 730,028 F1 · kind: The sales reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell-to-cover" transaction and do not represent discretionary transactions by the reporting person. F2 · price: The price reported in this line item is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $26.50 to $27.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein to the block trades. Read SEC document |
| August 12, 2026 Filed Aug 15, 2026 00:46 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 109,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001725092-26-000013 · form4-08152026_120800.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 764,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:32 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock · Derivative | 327,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001725092-26-000006 · form4-07102026_110711.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,537 Underlying: Common Stock · 327,537 shares Expires not disclosed F2 · derivative.exercise_price: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.exercise_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. F2 · derivative.expiration_date: Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 23:32 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 327,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001725092-26-000006 · form4-07102026_110711.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,074 F1 · shares: Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock Warrants (Right to Buy) · Derivative | 45,453 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001725092-26-000004 · form4-06032026_090611.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,453 Underlying: Common Stock · 45,453 shares Expires 2031-05-04 F2 · price: On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026. F3 · ownership.nature: The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:30 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchasePre-Funded Warrants (Right to Buy) · Derivative | 90,906 | $11.00 Strike: $0.00 | $999,966.00 |
DisclosureSEC source: 0001725092-26-000004 · form4-06032026_090611.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 90,906 Underlying: Common Stock · 90,906 shares Expires not disclosed F2 · price: On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026. F1 · derivative.expiration_date: The securities do not have an expiration date. F3 · ownership.nature: The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023. Read SEC document |
| June 01, 2026 Filed Jul 30, 2026 20:35 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock Warrants (Right to Buy) · Derivative | 45,453 | Not disclosed Strike: $11.00 | Not disclosed |
DisclosureSEC source: 0001725092-26-000009 · form4a-07302026_080752.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,453 Underlying: Common Stock · 45,453 shares Expires 2031-05-04 F1 · kind: This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged. F3 · price: On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026. F4 · ownership.nature: The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023. Read SEC document |
| June 01, 2026 Filed Jul 30, 2026 20:35 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | GrantPre-Funded Warrants (Right to Buy) · Derivative | 90,906 | $11.00 Strike: $0.00 | $999,966.00 |
DisclosureSEC source: 0001725092-26-000009 · form4a-07302026_080752.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 90,906 Underlying: Common Stock · 90,906 shares Expires not disclosed F1 · kind: This amendment is filed solely to correct the transaction code reported in Column 4 of Table II. The transactions reported herein were approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended, prior to the issuance of the applicable securities. All other information in the original filing remains unchanged. F3 · price: On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026. F2 · derivative.expiration_date: The securities do not have an expiration date. F4 · ownership.nature: The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023. Read SEC document |
| May 03, 2026 Filed May 7, 2026 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 655,074 | $0.00 Strike: $30.42 | $0.00 |
DisclosureSEC source: 0001193125-26-211806 · ownership.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655,074 Underlying: Common Stock · 655,074 shares Expires 2036-05-02 F1 · derivative.exercise_date: This stock option becomes exercisable in 48 equal monthly installments beginning on April 30, 2026. Read SEC document |
| May 03, 2026 Filed May 7, 2026 20:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantCommon Stock | 327,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-211806 · ownership.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,537 Read SEC document |
| May 14, 2025 Filed May 15, 2025 21:19 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001593968-25-000609 · primary_01.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2035-05-14 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 00:31 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 1,333 | $0.00 Strike: $11.00 | $0.00 |
DisclosureSEC source: 0001593968-24-000833 · primary_01.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333 Underlying: Common Stock · 1,333 shares Expires 2034-06-05 F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 22:18 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | SaleCommon Stock | 9,961 | $6.63 | $66,024.50 |
DisclosureSEC source: 0001962918-24-000036 · wk-form4_1712182665.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,577,374 F1 · kind: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $6.655 and no less than $6.600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 00:04 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | SaleCommon Stock | 15,701 | $7.60 | $119,402.96 |
DisclosureSEC source: 0001962918-24-000015 · wk-form4_1708646670.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,587,335 F1 · kind: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $7.75 and no less than $7.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:42 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 413,498 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001962918-24-000012 · wk-form4_1705016551.xml · derivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 413,498 Underlying: Common Stock · 413,498 shares Expires 2034-01-08 F2 · derivative.exercise_date: All of the shares subject to the option shall vest on July 9, 2025 if on that date the 30-day volume weighted average price of the Issuer's Common Stock for the immediately preceding 30 days meets or exceeds $22.00 per share, subject to the Reporting Person's continued service as of such vesting date, with such option being forfeited if such goal is not achieved. F2 · derivative.expiration_date: All of the shares subject to the option shall vest on July 9, 2025 if on that date the 30-day volume weighted average price of the Issuer's Common Stock for the immediately preceding 30 days meets or exceeds $22.00 per share, subject to the Reporting Person's continued service as of such vesting date, with such option being forfeited if such goal is not achieved. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 23:42 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 964,829 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001962918-24-000012 · wk-form4_1705016551.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 964,829 Underlying: Common Stock · 964,829 shares Expires 2034-01-08 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on January 9, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 23:09 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | SaleCommon Stock | 10,691 | $7.41 | $79,188.24 |
DisclosureSEC source: 0001962918-24-000002 · wk-form4_1704409733.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,603,036 F1 · kind: The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy certain tax obligations of the Reporting Person incurred with the vesting and settlement of certain Restricted Stock Units, and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices no more than $7.62 and no less than $7.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 1,293 shares of Common Stock acquired pursuant to the Issuer's 2023 Employee Stock Purchase Plan ("ESPP"), for the purchase period of June 15, 2023 to December 14, 2023. This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's Common Stock on December 14, 2023. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 21:55 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 132,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000036 · wk-form4_1696629327.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 487,205 F1 · kind: As part of its dissolution, Woodland Hills Partner LLC (the "LLC"), distributed its 1,161,747 shares of common stock to its limited partners. As part of that distribution, 132,236 shares were distributed to the Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing. The remaining 1,029,511 shares were distributed to other LLC limited partners not under the ownership or control of, or otherwise affiliated with, the Reporting Person. As a result, those 1,029,511 shares are no longer beneficially owned by the Reporting Person. F3 · ownership.nature: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 21:55 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 1,161,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000036 · wk-form4_1696629327.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: As part of its dissolution, Woodland Hills Partner LLC (the "LLC"), distributed its 1,161,747 shares of common stock to its limited partners. As part of that distribution, 132,236 shares were distributed to the Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20. This distribution arises from the purchase of preferred stock by the Reporting Person as a limited partner in the LLC on the same pricing terms as the other participating investors in each round of financing. The remaining 1,029,511 shares were distributed to other LLC limited partners not under the ownership or control of, or otherwise affiliated with, the Reporting Person. As a result, those 1,029,511 shares are no longer beneficially owned by the Reporting Person. F2 · ownership.nature: Shares held directly by Woodland Hills Partner LLC, for which the Reporting Person serves as a managing member. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 22:49 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantCommon Stock | 842,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001962918-23-000021 · wk-form4_1692398937.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,612,434 F1 · shares: Represents Restricted Stock Units (RSUs). 1/4 of the RSUs will vest on May 15, 2024 and the remaining RSUs will vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 18, 2023 Filed May 19, 2023 22:31 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001593968-23-000844 · primary_01.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-18 Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 774,788 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · derivative · entry 18 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,788 Underlying: Common Stock · 774,788 shares Expires 2033-05-03 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F12 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F3 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherEmployee Stock Option (right to buy) · Derivative | 774,788 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · derivative · entry 17 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 774,788 shares Expires 2033-05-03 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F12 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F3 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 183,433 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · derivative · entry 16 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 183,433 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F3 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2 · ownership.nature: Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 978,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · derivative · entry 15 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 978,314 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F3 · derivative.underlying: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2 · ownership.nature: Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 5,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 14 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,070 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11 · ownership.nature: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 5,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 13 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F11 · ownership.nature: Shares held directly by Susie Jun, Trustee of the Susie Jun Trust U/A/D September 23, 2005, for which the Reporting Person's spouse serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 349,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 12 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 349,898 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10 · ownership.nature: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 349,898 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 11 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F10 · ownership.nature: Shares held directly by Susie Jun 2020 Gift Trust dtd 7/16/20, for which the Reporting Person serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 354,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 10 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 354,969 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9 · ownership.nature: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 354,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 9 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F9 · ownership.nature: Shares held directly by Lin Family 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse shares voting and investment power. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 354,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 8 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 354,969 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8 · ownership.nature: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 354,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 7 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F8 · ownership.nature: Shares held directly by Shao-Lee Lin 2020 Gift Trust Dtd 7/16/20, for which the Reporting Person's spouse serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 677,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 6 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 677,813 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · ownership.nature: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 677,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 5 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F7 · ownership.nature: Shares held directly by Shao-Lee Lin, Trustee of the Shao-Lee Lin Trust u/a/d September 23, 2005, for which the Reporting Person serves as trustee. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | Tax withholdingCommon Stock | 337,179 | $24.69 | $8,324,949.51 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 4 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770,034 F5 · shares: Represents shares that have been withheld by the Issuer to satisfy the income tax withholding obligations in connection with the net settlement of RSUs, and not a discretionary sale by the Reporting Person. The Common Stock settled and RSUs held by the Reporting Person remain subject to the terms of a lock-up agreement by and between the Reporting Person and certain underwriters of the IPO. F6 · balance_after: Represents 303,237 shares of Common Stock and 466,797 RSUs after the net settlement of vested RSUs into shares of Common Stock upon the completion of the IPO. The remaining RSUs will continue to settle into shares of Common Stock as they vest thereafter, subject to the Reporting Person's continued service. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherCommon Stock | 1,107,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 3 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,107,213 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F4 · shares: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | OtherClass A Common Stock | 1,107,213 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 2 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · kind: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F4 · shares: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| May 09, 2023 Filed May 12, 2023 00:50 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | ConversionCommon Stock | 1,161,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-028862 · doc4.xml · nonDerivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,161,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F1 · price: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the Issuer's initial public offering of Common Stock (the "IPO"), all shares of preferred stock automatically converted into shares of Common Stock. F2 · ownership.nature: Shares held directly by Woodland Hills Partners LLC, for which the Reporting Person serves as a managing member. Read SEC document |
| May 04, 2023 Filed May 4, 2023 23:57 UTC | ACELYRIN, Inc. SLRN · Entity 79310 | GrantEmployee Stock Option (right to buy) · Derivative | 774,788 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027509 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774,788 Underlying: Class A Common Stock · 774,788 shares Expires 2033-05-03 F1 · derivative.exercise_date: 1/4 of the shares subject to the option vest on May 4, 2024, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. F2 · derivative.underlying: Each share of Class A Common Stock shall be reclassified into one share of Common Stock immediately prior to the completion of the Issuer's initial public offering of Common Stock. Read SEC document |
| October 26, 2022 Filed Oct 27, 2022 16:57 UTC | Third Harmonic Bio, Inc. THRD · Entity 76517 | GrantStock Option (right to buy) · Derivative | 13,667 | $0.00 Strike: $17.83 | $0.00 |
DisclosureSEC source: 0001209191-22-054729 · doc4.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 21:49 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001593968-22-001109 · primary_01.xml · derivative · entry 1 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Surrozen, Inc. Common Stock · 20,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options fully vest and become exercisable on the one-year anniversary of the grant date, subject to the reporting person's continuous service as a director. Read SEC document |
| September 28, 2020 Filed Sep 28, 2020 17:25 UTC | Principia Biopharma Inc. PRNB · Entity 146423 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,240 | Not disclosed Strike: $62.66 | Not disclosed |
DisclosureSEC source: 0001209191-20-052231 · doc4.xml · derivative · entry 3 Lin Shao-Lee · CIK 0001725092 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,240 shares Expires 2030-06-03 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.